Drugs / T60c
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06082557 | Oct 2023 → Mar 2025 | cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T60c | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06082557 ↗ |
| Modality | Cell therapy | “This is an open-labeled, single-arm, multiple-dose escalation and single-dose expansion clinical study of cell therapy” NCT06082557 ↗ |
| Route | Intravenous | “The obtained T60c is used for one-time intravenous infusion.” NCT06082557 ↗ |